Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.

[1]  M. Stafford-Smith,et al.  Activated Clotting Time Systems Vary In Precision And Bias And Are Not Interchangeable When Following Heparin Management Protocols During Cardiopulmonary Bypass , 2002, Journal of clinical monitoring and computing.

[2]  J. Tcheng,et al.  Implementing a New Method for Activated Clotting Time:: Comparisons Between the Hemochron and the Actalyke-MaxACT Systems , 2003 .

[3]  R. Hetzer,et al.  Hemostatic Activation and Inflammatory Response during Cardiopulmonary Bypass: Impact of Heparin Management , 2002, Anesthesiology.

[4]  S. Hossain,et al.  An Investigation of a New Activated Clotting Time “MAX-ACT” in Patients Undergoing Extracorporeal Circulation , 2001, Anesthesia and analgesia.

[5]  A. Usui,et al.  Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. , 2000, Artificial organs.

[6]  B. Coller,et al.  In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. , 1997, Circulation.

[7]  E. Spitznagel,et al.  More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT , 1996, Thrombosis and Haemostasis.

[8]  D. Jobes,et al.  Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. , 1995, The Journal of thoracic and cardiovascular surgery.

[9]  E. Spitznagel,et al.  The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. , 1995, The Journal of thoracic and cardiovascular surgery.

[10]  E. Spitznagel,et al.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[11]  J. Ferguson,et al.  Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[12]  M. Laato,et al.  Use of activated clotting time to monitor anticoagulation during cardiac surgery. , 1984, Scandinavian journal of thoracic and cardiovascular surgery.

[13]  K. Pi.  Lack of correction between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1983, Annals of surgery.

[14]  B. Akl,et al.  Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. , 1980, The Journal of thoracic and cardiovascular surgery.

[15]  C. Kisker,et al.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.

[16]  J. Verska.  Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. , 1977, The Annals of thoracic surgery.

[17]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[18]  P. Hattersley.  Activated coagulation time of whole blood. , 1966, JAMA.